Journals / Viral Hepatitis Journal / 2017 / Cilt: 23 - Sayı: 2

Can HBsAg Be Used as a Viral Replication Marker in Chronic Hepatitis B Patients?

Kronik Hepatit B Hastalarında HBsAg Viral Replikasyon Göstergesi Olarak Kullanılabilir mi?

Pages
55–59
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, this correlation is not practical in monitoring treatment response and replication

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Monitoring hepatitis B virus (HBV) treatment responses and virus replication is performed with molecular tests.
📊
Key Findings & Data:We aimed to evaluate the correlation between serum hepatitis B surface antigen (HBsAg) and alanine aminotransferase (ALT) levels and HBV DNA level in hepatitis B e antigen (HBeAg) +/- patients and detect whether HBsAg can be used as a surrogate replication marker instead of HBV DNA.Material and Methods: A retrospective study was conducted in 59 chronic hepatitis B patients.
💡
Conclusion & Impact:However, this correlation is not practical in monitoring treatment response and replication
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Monitoring hepatitis B virus (HBV) treatment responses and virus replication is performed with molecular tests. However, these tests are either expensive or invasive. A new and more practical marker is needed. We aimed to evaluate the correlation between serum hepatitis B surface antigen (HBsAg) and alanine aminotransferase (ALT) levels and HBV DNA level in hepatitis B e antigen (HBeAg) +/- patients and detect whether HBsAg can be used as a surrogate replication marker instead of HBV DNA.Material and Methods: A retrospective study was conducted in 59 chronic hepatitis B patients. Serum ALT, HBsAg and HBeAg levels and HBV DNA levels were recorded. The results were analysed with the Mann-Whitney U test and Spearman correlation coefficient. A p value of ≤0.05 was considered statistically significant. Sequential results were compared using Blant-Alpman plot. Results: The patients were grouped as HBeAg-positive (37.2%) and HBeAg-negative (62.8%). Serum ALT levels were elevated in 82% of HBeAg-positive and 70.2% of HBeAg-negative subjects. There was a statistically significant difference in HBsAg levels between the groups (p 0.05). A statistically significant negative correlation was detected between HBsAg and HBV DNA levels in HBeAg-positive patients. No correlation was found between HBsAg and HBV DNA levels in HBeAg-negative subjects (p<0.05). In both HBeAg-positive and -negative individuals, there was a positive correlation between serum ALT and HBV DNA levels (p<0.05). BlantAlpman graph did not show an appropriate profile.Conclusion: We found a negative correlation between HBsAg and HBV DNA levels in HBeAg-positive patients. However, this correlation is not practical in monitoring treatment response and replication

Özet

Amaç: Hepatit B virüsüne (HBV) olan tedavi cevabı ve virüs replikasyonun monitorizasyonu moleküler yöntemlerle yapılmaktadır. Ancak bu yöntemler ya pahalı ya da invazivdir. Bu konu da daha uygulanabilir bir belirtece ihtiyaç vardır. Bu çalışmada hepatit B e antijen (HBeAg) +/- hastalarda hepatit B yüzey antijeni (HBsAg), alanin aminotransferaz (ALT) ve HBV DNA düzeyleri arasındaki korelasyonu ve HBsAg'nin HBV DNA yerini alabilecek bir replikasyon göstergesi olarak kullanılıp kullanılamayacağını araştırmayı hedefledik.Gereç ve Yöntemler: Çalışmamız 59 kronik hepatit B hastası ile retrospektif olarak yürütülmüştür. Hastaların serum ALT, HBsAg, HBeAg ve HBV DNA düzeyleri kayıt edilmiştir. Sonuçlar Mann-Whitney U ve Spearman korelasyon testleri aracılığıyla değerlendirilmiştir. P 0,05). HBeAg pozitif grupta HBsAg ve HBV DNA düzeyleri arasında, anlamlı negatif korelasyon saptanırken (p<0,05), HBeAg negatif olanlarda, HBsAg ve HBV DNA düzeyleri arasında korelasyon yoktu. Hem HBeAg pozitif hem de negatif grupta, serum ALT ve HBV DNA düzeyleri arasında pozitif bir korelasyon vardı (p<0,05). Blant-Alpman grafiği anlamlı bir profil göstermedi.Sonuç: HBeAg pozitif hastalarda HBsAg ve HBV DNA düzeyleri arasında negatif bir korelasyon saptadık. Ancak bu korelasyon ne tedavinin monitorizasyonunda ne de replikasyonun takibinde kullanıma uygun değildir

🔖

Cite This Article

UZUNOĞLU, E., ŞAHİN, A. M., AVCI, E., KUTLU, H., GÜNTEPE, G. (2017). Can HBsAg Be Used as a Viral Replication Marker in Chronic Hepatitis B Patients?. Viral Hepatitis Journal, Cilt: 23 - Sayı: 2, 55–59. https://ajindex.com/articles/332080

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Wright TL. Introduction to chronic hepatitis B infection. Am J Gastroenterol. 2006;101(Suppl 1):1-6
  2. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227-242
  3. Ganji A, Esmaeilzadeh A, Ghafarzadegan K, Helalat H, Rafatpanah H, Mokhtarifar A. Correlation between HBsAg quantitative assay results and HBV DNA levels in chronic HBV. Hepat Mon. 2011;11:342-345
  4. Li W, Zhao J, Zou Z, Liu Y, Li B, Sun Y, Li X, Liu S, Cai S, Yao W, Xin S, Lu F, Xu D. Analysis of hepatitis B virus intrahepatic covalently closed circular DNA and serum viral markers in treatment-naive patients with acute and chronic HBV infection. PLoS One. 2014;9:e89046
  5. Ozdil B, Cosar AM, Akkiz H, Sandikci MU, Kece C. Negative correlation between viral load and HBsAg levels in chronic HBVinfected patients. Arch Virol. 2009;154:1451-1455
  6. Saglik I, Mutlu D,Ongut G, Guvenc H.I,Akbas H, Ogunc D, Colak D. Comparison of HBsAg and HBeAg levels with HBV DNA and ALT levels in patients with chronic hepatitis B infections. Viral Hepat J. 2013;19;119-122
  7. Sener AG, Kirdar S, Serter M, Afsar I, Demir EM, Ceylan C, Aydın N. Investigation of the relationship between serum nitric oxide levels, HBV-DNA and ALT levels in chronic hepatitis B patients. Mikrobiyol Bul. 2009;43:83-89
  8. Zeng LY, Lian JS, Chen JY, Jia HY, Zhang YM, Xiang DR, Yu L, Hu JH, Lu YF, Zheng L, Li LJ, Yang YD. Hepatitis B surface antigen levels during natural history of chronic hepatitis B: a Chinese perspective study. World J Gastroenterol. 2014;20:9178-9184
  9. Martinot-Peignoux M, Carvalho-Filho R, Lapalus M, NettoCardosso AC, Lada O, Batrla R, Krause F, Asselah T, Marcellin P. Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naive,. e antigen-positive patients. J Hepatol. 2013;58:1089-1095
  10. Seto WK, Wong DK, Fung J, Ip PPC, Yuen JC, Hung IF, Lai CH, Yuen MF. High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B. PLoS One. 2012;7:e43087
  11. Jaroszewicz J, Calle Serrano B, Wursthorn K, Deterding K, Schlue J, Raupach R,Flisiak R, Bock CT, Manns MP, Wedemeyer H, Cornberg M. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus(HBV)-infection: a European perspective. J Hepatol. 2010;52:514-522
  12. Nguyen T, Thompson AJ, Bowden S, Croagh C, Bell S, Desmond PV, Levy M, Locarnini SA. Hepatitis